Muvagyn (Lactobacillus Gasseri Dsm 14869, Lactobacillus Rhamnosus Dsm 14870)

The two lactobacilli strains colonise the vaginal mucosa and ferment glycogen to produce lactic acid, which lowers the vaginal pH. The acidic environment, together with bacteriocins and hydrogen peroxide released by the bacteria, inhibits growth of pathogenic microbes and promotes a stable, protective microbiome.

The specific dosing regimen for Muvagyn is determined by the prescribing healthcare professional based on the individual’s condition and treatment goals. Typical regimens involve one vaginal applicator or tablet inserted daily for a short course, but exact frequency and duration should follow the prescriber’s instructions.

Safety data for Muvagyn in pregnancy and lactation are limited. Women who are pregnant or breastfeeding should discuss use with their obstetrician or qualified healthcare provider to weigh potential benefits against any unknown risks.

To order Muvagyn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Muvagyn contains two clinically studied strains—Lactobacillus gasseri DSM 14869 and Lactobacillus rhamnosus DSM 14870—known for strong acid‑producing capacity and adherence to vaginal epithelium. Compared with generic multi‑strain products, these specific strains have demonstrated consistent colonisation and pH‑lowering effects in clinical studies, offering a targeted approach to restoring vaginal health.

Store Muvagyn at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to preserve bacterial viability. Do not refrigerate unless the packaging specifically indicates a cold‑chain requirement.

Muvagyn is intended for vaginal administration. The product is supplied as a tablet or applicator that is inserted into the vagina according to the prescriber’s instructions, typically using a clean fingertip or applicator device. No oral ingestion is required.

Although rare, serious adverse reactions can include allergic responses such as rash, swelling, or difficulty breathing, and in severely immunocompromised patients, a possible systemic infection. Any signs of severe pain, fever, or persistent irritation should prompt immediate medical evaluation.

Muvagyn should be avoided by individuals with a known hypersensitivity to any Lactobacillus species. Patients with severely compromised immune systems should use it only under close medical supervision. Pregnant or breastfeeding women should consult their healthcare provider before starting therapy.